Corcept Therapeutics reported an insider sale by William Guyer, its Chief Development Officer, who sold 20,000 shares of the companys common stock on April 7, 2026. The block generated proceeds of $819,400, with a weighted average sale price of $40.97 per share. Reported individual trade prices ranged from $40.85 to $41.30.
On the same date, Guyer exercised stock options to purchase 20,000 shares at an exercise price of $21.65 each, for a total exercise cost of $433,000. Following the paired transactions, his direct beneficial ownership is reported at 2,231 shares of Corcept Therapeutics common stock.
Execution mechanics and plan
The share sale was carried out under a pre-established 10b5-1 trading plan that Guyer adopted on November 27, 2024. The filing indicates the sale followed the predetermined terms of that plan rather than an ad hoc open-market decision.
Share-price context and valuation note
At the time of the report, Corcepts stock was trading at $41.88. Over the prior six months the share price had declined by 53 percent according to InvestingPro data cited in the filing. Despite recent weakness, InvestingPro analysis noted that the stock still appears undervalued against its Fair Value and listed the company among its most undervalued coverage candidates, with a full Pro Research Report available for subscribers.
Corporate developments and insider activity
Corcept recently received regulatory approval for Lifyorli, described as a selective glucocorticoid receptor antagonist, for use in combination with nab-paclitaxel to treat adults with platinum-resistant ovarian cancer. The approval, which was granted ahead of schedule, was supported by results from the ROSELLA trial comprising 381 patients. In the wake of the approval, Wolfe Research moved its rating on Corcept to Peerperform from Underperform.
Insider buying has also been recorded: director G. Leonard Baker Jr. increased his stake by acquiring 100,000 shares, as disclosed in a Form 4 filing.
Legal proceedings
The company is also named in a securities class action complaint, filed by the law firm Kahn Swick & Foti. The suit concerns investors who purchased Corcept shares between October 31, 2024, and December 30, 2025. The filing window for lead plaintiff applications in that case closes on April 21, 2026, and the action is pending in the United States District Court for the Northern District of California.
What the filings show
- Sale: 20,000 shares sold on April 7, 2026 for $819,400; weighted average price $40.97; trade prices ranged $40.85 to $41.30.
- Option exercise: 20,000 options exercised at $21.65 per share, totaling $433,000.
- Direct ownership after transactions: 2,231 shares.
- Sale executed under a 10b5-1 plan adopted November 27, 2024.
The filings and corporate announcements together offer a snapshot of recent insider activity, regulatory progress, analyst reaction, and litigation affecting Corcept Therapeutics. Investors seeking more detailed valuation and research data are referenced to the comprehensive Pro Research Report available for the company through InvestingPro.